Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $3.05 billion. The enterprise value is $2.65 billion.
| Market Cap | 3.05B |
| Enterprise Value | 2.65B |
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 79.79 million shares outstanding. The number of shares has increased by 1.76% in one year.
| Current Share Class | 79.79M |
| Shares Outstanding | 79.79M |
| Shares Change (YoY) | +1.76% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 110.12% |
| Float | 79.35M |
Valuation Ratios
The trailing PE ratio is 35.43 and the forward PE ratio is 21.82.
| PE Ratio | 35.43 |
| Forward PE | 21.82 |
| PS Ratio | 5.63 |
| Forward PS | 5.02 |
| PB Ratio | 2.27 |
| P/TBV Ratio | 6.21 |
| P/FCF Ratio | 19.65 |
| P/OCF Ratio | 18.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.45, with an EV/FCF ratio of 17.07.
| EV / Earnings | 30.14 |
| EV / Sales | 4.90 |
| EV / EBITDA | 25.45 |
| EV / EBIT | 32.06 |
| EV / FCF | 17.07 |
Financial Position
The company has a current ratio of 9.31, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.31 |
| Quick Ratio | 8.72 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.31 |
| Debt / FCF | 0.25 |
| Interest Coverage | 82,729.00 |
Financial Efficiency
Return on equity (ROE) is 6.93% and return on invested capital (ROIC) is 8.53%.
| Return on Equity (ROE) | 6.93% |
| Return on Assets (ROA) | 3.76% |
| Return on Invested Capital (ROIC) | 8.53% |
| Return on Capital Employed (ROCE) | 5.99% |
| Weighted Average Cost of Capital (WACC) | 14.43% |
| Revenue Per Employee | $717,540 |
| Profits Per Employee | $116,574 |
| Employee Count | 755 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 6.43 |
Taxes
In the past 12 months, Veracyte has paid $2.73 million in taxes.
| Income Tax | 2.73M |
| Effective Tax Rate | 3.01% |
Stock Price Statistics
The stock price has increased by +24.35% in the last 52 weeks. The beta is 1.88, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | +24.35% |
| 50-Day Moving Average | 33.74 |
| 200-Day Moving Average | 36.10 |
| Relative Strength Index (RSI) | 59.88 |
| Average Volume (20 Days) | 978,341 |
Short Selling Information
The latest short interest is 6.87 million, so 8.61% of the outstanding shares have been sold short.
| Short Interest | 6.87M |
| Short Previous Month | 6.45M |
| Short % of Shares Out | 8.61% |
| Short % of Float | 8.66% |
| Short Ratio (days to cover) | 7.03 |
Income Statement
In the last 12 months, Veracyte had revenue of $541.74 million and earned $88.01 million in profits. Earnings per share was $1.08.
| Revenue | 541.74M |
| Gross Profit | 394.97M |
| Operating Income | 82.73M |
| Pretax Income | 90.75M |
| Net Income | 88.01M |
| EBITDA | 104.21M |
| EBIT | 82.73M |
| Earnings Per Share (EPS) | $1.08 |
Balance Sheet
The company has $439.06 million in cash and $39.33 million in debt, with a net cash position of $399.73 million or $5.01 per share.
| Cash & Cash Equivalents | 439.06M |
| Total Debt | 39.33M |
| Net Cash | 399.73M |
| Net Cash Per Share | $5.01 |
| Equity (Book Value) | 1.34B |
| Book Value Per Share | 16.85 |
| Working Capital | 466.06M |
Cash Flow
In the last 12 months, operating cash flow was $166.16 million and capital expenditures -$10.82 million, giving a free cash flow of $155.34 million.
| Operating Cash Flow | 166.16M |
| Capital Expenditures | -10.82M |
| Depreciation & Amortization | 21.48M |
| Net Borrowing | n/a |
| Free Cash Flow | 155.34M |
| FCF Per Share | $1.95 |
Margins
Gross margin is 72.91%, with operating and profit margins of 15.27% and 16.25%.
| Gross Margin | 72.91% |
| Operating Margin | 15.27% |
| Pretax Margin | 16.75% |
| Profit Margin | 16.25% |
| EBITDA Margin | 19.24% |
| EBIT Margin | 15.27% |
| FCF Margin | 28.67% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.76% |
| Shareholder Yield | -1.76% |
| Earnings Yield | 2.88% |
| FCF Yield | 5.09% |
Analyst Forecast
The average price target for Veracyte is $44.86, which is 17.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.86 |
| Price Target Difference | 17.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 10.41% |
| EPS Growth Forecast (5Y) | 18.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 17.95 and a Piotroski F-Score of 7.
| Altman Z-Score | 17.95 |
| Piotroski F-Score | 7 |